Skip to main content
Donate

Families & Caregivers

Global Science Summit & Gala

5 photos of the summit and gala

The 2026 FAST Global Science Summit & Gala

Our biggest event of the year will be held at the Hyatt Regency Orlando November 5-7, 2026.

Registration is now open

  1. Register for the Global Science Summit & purchase your tickets to the FAST Gala

    1. Registration for the Global Science Summit is free for all ages.

    2. Gala is for 18+ adults and tickets are $250 USD each.

  2. Book your hotel room at the Hyatt Regency Orlando here.

    1. NOTE: We have limited number of rooms available at the rate of $211 USD + tax per night

    2. After that, rooms will be available at $259 USD + tax per night.

Key Registration Dates

  • Aug 3: In-Person and virtual registration opens

  • Aug 31: Deadline for early bird registration and have your loved one featured in our Gala video

  • Oct 14: Hotel block closes

  • Oct 27: In-Person registration closes

Weekend Agenda

Thursday, November 5:

Friday, November 6:

  • All Day: Global Science Summit

Saturday, November 7:

  • Morning: Global Science Summit

  • Evening: FAST Gala, an 18+ formal celebration

International Guests

If you live outside of the United States and will need a visa to travel to the US, please consider applying now. If you would like FAST to write you a letter of invitation for you to enclose with your visa application, we are happy to do so. To request a letter of invitation, please email events@cureangelman.org and provide the full names of the people in your family who will attend.

Frequently Asked Questions

If you've never attended this event, please check out the FAQs. If you have a question that is not listed, please email events@cureangelman.org

Sponsors and Exhibitors

If your business or organization is interested in sponsoring or exhibiting at the event, please email events@cureangelman.org.

This is the biggest science and drug development event devoted to Angelman syndrome.

Learn more about the event.

The Global Science Summit is preceded by the Translational Research Symposium and Angelman Syndrome Biomarker and Outcome Measure Consortium (A-BOM) meeting which will be on November 5, 2026 in Orlando, FL. This is an event for the research community by invite only. If you are interested in attending, email events@cureangelman.org.

TRS-ABOM

What is A-BOM?

Registration sign at TRS-ABOM in 2024.

2025 Global Science Summit & Gala Recap

FAST Angelman Syndrome News

Rugonersen Development Update: First Participant Dosed in the Phase 3 BEACON Trial

Nobel Laureate Frances Arnold Brings Directed Evolution to Angelman Syndrome Research

Dream Big: One Family's Journey from the Altar to the Start Line

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Ange...

46 Days. 14 States. 2,725 Miles. One Reason: Briar.

Spring Advocacy Update: Educating, Advocating, and Building Momentum

Nonprofit Leader and Attorney Alice Rodd O’Rourke, JD Joins FAST Board of Directors

FAST Brings Angelman Syndrome Community Perspective to FDA Rare Disease Roundtable

A Sister-Led Sip & Shop Turns Jewelry Into Support for FAST

Update on Rugonersen Development and Planned Phase 3 Study  (BEACON)  

Non-viral delivery gene editing takes an important step forward for Angelman syndrome

FAST LATAM Brings Families and Research Together in Mexico City

FAST at ASGCT 2026

Using Vocalization Testing to Improve Detection of Treatment Effects in Angelman Syndrome Models

FAST's Action Council member, Joe D'Orazio, shares his story with CNBC Cures

Career Development Awards Expand the Next Wave of Angelman Syndrome Research

2026 Congressional Advocacy Day: Recap and Successes

Important update on alogabat, an investigational therapy in development for Angelman syndrome

FAST Poland hosts second nationwide conference, "From Diagnosis to Therapy."

Measuring Communication in Angelman Syndrome to Support Better Trials

Rugonersen Development Update: First Participant Dosed in the Phase 3 BEACON Trial

Nobel Laureate Frances Arnold Brings Directed Evolution to Angelman Syndrome Research

Dream Big: One Family's Journey from the Altar to the Start Line

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Ange...

46 Days. 14 States. 2,725 Miles. One Reason: Briar.

Spring Advocacy Update: Educating, Advocating, and Building Momentum

Nonprofit Leader and Attorney Alice Rodd O’Rourke, JD Joins FAST Board of Directors

FAST Brings Angelman Syndrome Community Perspective to FDA Rare Disease Roundtable

A Sister-Led Sip & Shop Turns Jewelry Into Support for FAST

Update on Rugonersen Development and Planned Phase 3 Study  (BEACON)  

Non-viral delivery gene editing takes an important step forward for Angelman syndrome

FAST LATAM Brings Families and Research Together in Mexico City

FAST at ASGCT 2026

Using Vocalization Testing to Improve Detection of Treatment Effects in Angelman Syndrome Models

FAST's Action Council member, Joe D'Orazio, shares his story with CNBC Cures

Career Development Awards Expand the Next Wave of Angelman Syndrome Research

2026 Congressional Advocacy Day: Recap and Successes

Important update on alogabat, an investigational therapy in development for Angelman syndrome

FAST Poland hosts second nationwide conference, "From Diagnosis to Therapy."

Measuring Communication in Angelman Syndrome to Support Better Trials

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.